Analysts Set Savara Inc. (NASDAQ:SVRA) PT at $5.60

Shares of Savara Inc. (NASDAQ:SVRA) have received a consensus recommendation of “Moderate Buy” from the five analysts that are currently covering the stock, MarketBeat Ratings reports. Two research analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $5.60.

Several research analysts have recently weighed in on SVRA shares. Evercore ISI reduced their price objective on Savara from $3.00 to $2.00 and set an “in-line” rating for the company in a research report on Wednesday, May 28th. Guggenheim reaffirmed a “buy” rating and set a $8.00 price objective (down from $9.00) on shares of Savara in a research report on Wednesday, May 28th. HC Wainwright lowered Savara from a “buy” rating to a “neutral” rating and dropped their target price for the stock from $6.00 to $2.00 in a report on Thursday, May 29th. Finally, Wells Fargo & Company dropped their target price on Savara from $8.00 to $7.00 and set an “overweight” rating on the stock in a report on Wednesday, May 28th.

Savara Stock Performance

SVRA opened at $2.41 on Friday. The firm has a market capitalization of $416.54 million, a P/E ratio of -5.02 and a beta of 0.31. The stock’s 50 day moving average price is $2.41 and its two-hundred day moving average price is $2.69. The company has a quick ratio of 14.91, a current ratio of 14.91 and a debt-to-equity ratio of 0.20. Savara has a 12-month low of $1.89 and a 12-month high of $4.74.

Savara (NASDAQ:SVRA) last announced its quarterly earnings results on Tuesday, May 13th. The company reported ($0.12) EPS for the quarter, meeting the consensus estimate of ($0.12). On average, equities analysts forecast that Savara will post -0.45 earnings per share for the current year.

Insider Buying and Selling at Savara

In related news, Director Richard J. Hawkins purchased 48,225 shares of the stock in a transaction that occurred on Friday, June 20th. The shares were bought at an average price of $2.04 per share, with a total value of $98,379.00. Following the acquisition, the director owned 115,466 shares of the company’s stock, valued at $235,550.64. This trade represents a 71.72% increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. 5.13% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in SVRA. Cibc World Markets Corp bought a new position in shares of Savara during the fourth quarter valued at about $33,000. XTX Topco Ltd bought a new position in shares of Savara during the fourth quarter valued at about $34,000. Ameriprise Financial Inc. bought a new position in shares of Savara during the fourth quarter valued at about $37,000. KLP Kapitalforvaltning AS bought a new position in shares of Savara during the fourth quarter valued at about $41,000. Finally, Hsbc Holdings PLC bought a new position in shares of Savara during the fourth quarter valued at about $48,000. 87.93% of the stock is currently owned by hedge funds and other institutional investors.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.